Insight

BAX protein’s role in cell death, a promising target for cancer therapy – Dana-Farber Cancer Institute

Photo taken from Dana-Farber Cancer Institute/LinkedIn

Jul 6, 2024, 14:44

BAX protein’s role in cell death, a promising target for cancer therapy – Dana-Farber Cancer Institute

Dana-Farber Cancer Institute shared a post on LinkedIn:

“For years, researchers have explored BAX protein’s role in cell death, a promising target for cancer therapy. New findings by Dana-Farber offer a starting point for drugs that inhibit BAX through a covalent mechanism.

‘BAX has been a focus of my lab for nearly 20 years,’ says Loren Walensky, MD, PhD, who began studying the protein as a postdoctoral fellow in the early 2000s. ‘Its enormous potential as a therapeutic target – if you activate it, you can cause malignant cells to die; if you shut it down, you can prevent healthy cells from dying – led us to explore its mechanism of activation and de-activation.’

Learn more here.”

Source: Dana-Farber Cancer Institute/LinkedIn

BAX protein cancer Cancer research cancer therapy cell death covalent inhibition Dana-Farber Cancer Institute drug development Loren Walensky MD PhD molecular biology OncoDaily Oncology therapeutic target

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage